Innovent Announces the Preclinical Results of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) were Published in Nature Cancer

ROCKVILLIE, Md. and SUZHOU, China, Aug. 7, 2023 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune,…